Related Experiment Video

Updated: May 1, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.5K

Lack of Association Between Transforming Growth Factor Beta 1 -509C/T and +915G/C Polymorphisms and Chronic Hepatitis

Armin Hosseini Razavi1, Pedram Azimzadeh2, Seyed Reza Mohebbi2

  • 1Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran ; Department of Microbiology, Faculty of Biological Sciences, Shahid Beheshti University, Tehran, IR Iran.

Hepatitis Monthly
|April 22, 2014
PubMed

Insights

This study found no association between specific transforming growth factor beta 1 (TGF-β1) gene variations and chronic hepatitis B in Iranian patients. These TGF-β1 polymorphisms do not appear to increase the risk of chronic hepatitis B infection.

Area of Science:

  • Immunology
  • Genetics
  • Hepatology

Background:

  • Chronic hepatitis B is a global health issue caused by the hepatitis B virus (HBV).
  • Transforming growth factor beta 1 (TGF-β1) has shown potential in suppressing HBV replication and mitigating liver damage.
  • Understanding genetic factors influencing HBV susceptibility is crucial for disease management.

Purpose of the Study:

  • To investigate the association between TGF-β1 gene polymorphisms (+915G/C and -509C/T) and chronic hepatitis B in an Iranian population.
  • To determine if these specific genetic variations influence the risk of developing chronic HBV infection.

Main Methods:

  • A case-control study involving 220 chronic hepatitis B patients and 220 healthy controls.
  • Genotyping of TGF-β1 +915G/C and -509C/T polymorphisms using PCR-Restriction Fragment Length Polymorphism (PCR-RFLP).
  • Sequencing of 10% of control samples to validate genotyping results.

Main Results:

  • No statistically significant differences in genotype distribution were found for either polymorphism between patients and controls.
  • Allele frequencies for both TGF-β1 polymorphisms were similar in the chronic hepatitis B group and the healthy control group.
  • The study did not identify any correlation between the evaluated TGF-β1 polymorphisms and chronic hepatitis B.

Conclusions:

  • The TGF-β1 -509C/T and +915G/C polymorphisms are not associated with chronic hepatitis B in the studied Iranian population.
  • These specific genetic variations do not appear to play a significant role in the susceptibility to chronic HBV infection.
  • Further research may explore other genetic or environmental factors contributing to chronic hepatitis B pathogenesis.
Abstract

Keywords:
Hepatitis B, ChronicPolymorphism, GeneticTransforming Growth Factor beta 1

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121